Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients
March 30, 2021 16:01 ET
|
Equillium
Itolizumab administered subcutaneously was safe and well tolerated in patients with systemic lupus erythematosus Dose-dependent changes in pharmacodynamic markers observed with subcutaneous dosing...
Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases
March 29, 2021 08:25 ET
|
Exagen Inc.
SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today...
Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 25, 2021 16:15 ET
|
Exagen Inc.
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten...
Exagen Inc. Announces Pricing of Public Offering of Common Stock
March 22, 2021 22:01 ET
|
Exagen Inc.
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of an underwritten public offering of...
Exagen Inc. Announces Proposed Public Offering of Common Stock
March 22, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it intends to offer and sell, subject to market and...
Exagen Inc. Reports Fourth Quarter and Full Year 2020 Results
March 16, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year...
BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
March 15, 2021 11:12 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based...
Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
March 15, 2021 08:00 ET
|
Equillium
EQUATE acute graft-versus host disease (aGVHD) study observed rapid response and durability through day 85 EQUATE aGVHD study reported a clinically meaningful reduction in corticosteroid...
Ronald L. Besser announces the publication of ‘The Origins of AIDS and Autism’
March 03, 2021 00:00 ET
|
Archway Publishing
YORK, Pa., March 03, 2021 (GLOBE NEWSWIRE) -- Recent release “The Origins of AIDS and Autism” (published by Archway Publishing) is a collaboration between the Life Laboratory of Spirit and author...
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 16, 2021
March 02, 2021 08:00 ET
|
Exagen Inc.
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the...